Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: Amdipharm UK Limited, Capital House, 85 King William Street, London EC4N 7BL, UK
Carbimazole 20 mg Tablets.
| Pharmaceutical Form |
|---|
|
Pale pink, uncoated, round, biconvex tablets marked with LINK C20 on one side and a scoreline on the reverse. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. |
Each tablet contains 20 mg of carbimazole.
Excipients with known effect: Lactose Anhydrous (125.35 mg per tablet).
For a full list of excipients see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Carbimazole |
Carbimazole, a thionamide, is a pro-drug which undergoes rapid and virtually complete metabolism to the active metabolite, thiamazole, also known as methimazole. The method of action is believed to be inhibition of the organification of iodide and the coupling of iodothyronine residues which in turn suppress the synthesis of thyroid hormones. |
| List of Excipients |
|---|
|
Anhydrous lactose |
The tablets are supplied in white, opaque 250 micron thermoformed PVC blister packs sealed with 20 micron lacquered aluminium foil containing 28, 56, 100 or 112 tablets.
Not all pack sizes may be marketed.
The heatseal coating lacquer of the aluminium foil consists of a PVC/PVAC co-polymer and polymethacrylate, with the outer side being a heat resistant lacquer based on polyester.
Amdipharm UK Limited, Capital House, 85 King William Street, London EC4N 7BL, UK
PL 20072/0240
08/05/2008
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
